Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04603629 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| PF-04603629 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | BIOLOGICAL | Subjects will be given either Placebo or PF-04603629. |
| PF-04603629 | BIOLOGICAL | Subjects will be given either Placebo or PF-04603629. The specific dose of PF-04603629 given depended on the Cohort to which the patient was assigned. Doses administered ranged from 1 mg to 70 mg. |
Inclusion Criteria: * Type 2 diabetes mellitus * Hb A1c lower or equal to 11% Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug all...
PF-04603629 is an investigational monoclonal antibody being developed for the treatment of Type 2 Diabetes Mellitus. It is a metabolic therapeutic that has been studied in a Phase 1 clinical trial. The drug is not yet approved and remains in clinical development.
PF-04603629 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company conducted a Phase 1 clinical trial of the drug in the United States.
PF-04603629 is in Phase 1 clinical development. A single-dose study in Type 2 diabetic subjects has been completed. The drug is investigational and has not been approved by regulatory authorities.
PF-04603629 has been studied in one completed Phase 1 clinical trial, identified as NCT00638313. This was a single-dose, randomized, double-blind, placebo-controlled study in 71 Type 2 diabetic subjects in the United States.
No alternative names for PF-04603629 have been disclosed. The drug is identified solely by its code name PF-04603629 in clinical trial records.